



**Supplemental Figure 1.** The effect of PEGPH20 on uptake of <sup>14</sup>C-gemcitabine (top) and <sup>18</sup>F-FAC (bottom), expressed as the tumor/muscle ratio in three pancreatic PDX models. Each circle represents one animal; horizontal lines represent the mean. A statistically significant difference (p<0.05) between control and PEGPH20 animals was noted once (¬).




**Supplemental Figure 2.** The effect of PEGPH20 on uptake of gemcitabine, expressed as the tumor/muscle ratio in a KPC-derived tumor model growing orthotopically in C57BL/6 mice. Each circle represents one animal; horizontal lines represent the mean. A statistically significant difference (p<0.05) between control and PEGPH20 animals was noted (¬).



Supplemental Figure 3. Biodistribution of <sup>14</sup>C-gemcitabine in control (blue) and PEGPH20 treated (orange)

C57BL/6 mice.



**Supplemental Figure 4.** Autoradiographs of <sup>18</sup>F-FAC distribution in two control KPC-derived orthotopic tumors and two PEGPH20 treated C57BL/6 mice. Activity hotspots are on the tumor periphery, matching the pattern observed in images of separate tumors, obtained by PET-MR.